GlassScriptPhysician profile
Ushaanthy Ravindran
NPI 1992237622
$6,163.62
in general payments reported to CMS, 2019-2025
38 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $260 · 2021: $167 · 2022: $570 · 2023: $1,729 · 2024: $1,841 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,896 · Gift: $119 · Education: $48.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,895.59 |
| Gift | $118.80 |
| Education | $48.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $894.37 | 2022-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $771.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $638.74 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $612.07 | 2020-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.80 | 2023-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $321.25 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $289.69 | 2022-2025 | Afrezza |
| Radius Health, INC. | $278.44 | 2023-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $261.64 | 2023-2025 | |
| Beta Bionics, INC. | $245.73 | 2023-2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $163.56 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $154.79 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $140.36 | 2023-2025 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $133.12 | 2022-2025 | Gvoke Hypopen |
| Medtronic, INC. | $85.05 | 2022-2025 | Minimed 780g, Minimed 770g |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $79.14 | 2023-2024 | Octagam Immune Globulin (Human) |
| Recordati_rare_diseases_inc. | $69.88 | 2023-2025 | Signifor Lar, Isturisa |
| Ascensia Diabetes Care US INC. | $65.74 | 2024 | |
| Abbvie INC. | $54.00 | 2024-2025 | |
| Madrigal Pharmaceuticals | $48.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbott Laboratories | $48.19 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $38.33 | 2024-2025 | Actemra |
| Fresenius Kabi USA, LLC | $32.54 | 2025 | Adalimumab-Aacf |
| Alexion Pharmaceuticals, INC. | $31.16 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $30.69 | 2023 | |
| Sandoz INC. | $24.60 | 2025 | |
| Embecta Corp. | $24.21 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $21.53 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $21.42 | 2024 | |
| Tandem Diabetes Care, INC. | $21.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $21.13 | 2023 | Nocdurna, Xyosted, Tlando |
| Pfizer INC. | $20.73 | 2023 | |
| Chiesi USA, INC. | $19.24 | 2024 | Mycapssa |
| Insulet Corporation | $19.06 | 2025 | Omnipod |
| Sequel Med Tech, LLC | $18.83 | 2025 | Twiist |
| Averitas Pharma INC. | $18.24 | 2024 | Qutenza |
| Eisai INC. | $15.62 | 2025 | |
| Cequr Corporation | $14.81 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushaanthy Ravindran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.